Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.220
0.00 (0.00%)
At close: Nov 18, 2025, 4:00 PM EST
1.280
+0.060 (4.91%)
After-hours: Nov 18, 2025, 5:38 PM EST
Rein Therapeutics Employees
Rein Therapeutics had 11 employees as of December 31, 2024. The number of employees decreased by 4 or -26.67% compared to the previous year.
Employees
11
Change (1Y)
-4
Growth (1Y)
-26.67%
Revenue / Employee
n/a
Profits / Employee
-$5,353,182
Market Cap
28.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11 | -4 | -26.67% |
| Dec 31, 2023 | 15 | 9 | 150.00% |
| Dec 31, 2022 | 6 | -3 | -33.33% |
| Dec 31, 2021 | 9 | 1 | 12.50% |
| Dec 31, 2020 | 8 | -5 | -38.46% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RNTX News
- 15 days ago - Why Is Rein Therapeutics Stock Trading Higher On Monday? - Benzinga
- 5 weeks ago - Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 2 months ago - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 3 months ago - Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 3 months ago - Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 - GlobeNewsWire
- 5 months ago - Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders - PRNewsWire
- 5 months ago - US FDA puts on hold Rein Therapeutics' lung disease drug trial - Reuters
- 6 months ago - Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire